Sun Pharma vs Cipla vs Dr Reddy's: Side-by-Side Comparison of India's Top Pharma Stocks

Sun Pharma vs Cipla vs Dr Reddy's Laboratories starts with the core numbers most investors compare across leading pharmaceutical companies: market capitalisation, valuation, profitability, and the 52-week trading range. Figures below are as of September 2026 and will shift with daily price moves.

Tap to Access Best Research Pieces on Univest

Also read – HDFC Bank vs ICICI Bank vs Axis Bank: Side-by-Side Comparison of Three Leading Private Banks

Sun Pharma vs Cipla vs Dr Reddy's Laboratories: Key Metrics at a Glance

Metric	Sun Pharma	Cipla	Dr Reddy's Laboratories
Market Cap (approx.)	Rs 4,70,534 crore	Rs 1,20,079 crore	Rs 97,407 crore
PE Ratio (TTM)	38.90	35.62	30.23
PB Ratio	5.63	3.49	2.57
ROE (%)	13.73%	11.26%	11.07%
52-Week High	Rs 2,046.90	Rs 1,673.00	Rs 1,414.90
52-Week Low	Rs 1,548.00	Rs 1,165.70	Rs 1,101.00
Dividend Yield	0.82%	0.88%	0.69%

Check the Univest Screener for live data

Valuation Comparison: PE and PB Ratios

On valuation, Dr Reddy's Laboratories trades at the lowest PE ratio of the three at 30.23, Cipla follows at 35.62, while Sun Pharma commands the highest PE at 38.90. The same pattern holds on price-to-book, with Dr Reddy's at 2.57 times book value, Cipla at 3.49 times, and Sun Pharma at 5.63 times.

Profitability Comparison: Return on Equity

On return on equity, Sun Pharma leads the trio at 13.73%, ahead of Cipla at 11.26% and Dr Reddy's Laboratories at 11.07%, a relatively tight spread between the second and third-largest of the three.

52-Week Trading Range Comparison

Sun Pharma has traded in the widest absolute price band of the three over the past 52 weeks, between Rs 1,548.00 and Rs 2,046.90, followed by Cipla between Rs 1,165.70 and Rs 1,673.00. Dr Reddy's Laboratories has moved in a narrower range of Rs 1,101.00 to Rs 1,414.90.

Download the Univest iOS App or Univest Android App to track Sun Pharma, Cipla and Dr Reddy's Laboratories live prices.

Dividend Yield Comparison

Cipla offers the highest dividend yield among the three at 0.88%, narrowly ahead of Sun Pharma at 0.82% and Dr Reddy's Laboratories at 0.69%, though dividend yields across large-cap pharma names remain modest compared with sectors like FMCG or IT.

What Should Investors Look at Beyond These Numbers?

Beyond the metrics above, investors comparing these three pharma majors should track each company's US generics pipeline and FDA inspection outcomes, domestic formulation growth, and specialty or branded portfolio expansion, since these factors often drive stock-specific moves more than trailing valuation ratios.

Also read – TCS vs Infosys vs Wipro: Side-by-Side Comparison of India's Top IT Services Stocks

Snapshot: Sun Pharma vs Cipla vs Dr Reddy's Laboratories is a widely searched comparison among investors tracking this sector. Sun Pharma vs Cipla vs Dr Reddy's Laboratories highlights differences in valuation. Sun Pharma vs Cipla vs Dr Reddy's Laboratories highlights differences in profitability. Sun Pharma vs Cipla vs Dr Reddy's Laboratories highlights differences in dividend yield. Sun Pharma vs Cipla vs Dr Reddy's Laboratories is best read as a factual snapshot rather than a recommendation.

In short: Sun Pharma vs Cipla vs Dr Reddy's Laboratories remains one of the most-searched sector comparisons on Dalal Street. Sun Pharma vs Cipla vs Dr Reddy's Laboratories draws attention every earnings season. Sun Pharma vs Cipla vs Dr Reddy's Laboratories is tracked closely by retail and institutional investors alike. Sun Pharma vs Cipla vs Dr Reddy's Laboratories numbers should always be checked live before acting.

Quick recap: Sun Pharma vs Cipla vs Dr Reddy's Laboratories. Sun Pharma vs Cipla vs Dr Reddy's Laboratories. Sun Pharma vs Cipla vs Dr Reddy's Laboratories data as of September 2026.

Conclusion

Sun Pharma vs Cipla vs Dr Reddy's Laboratories highlights how differently three leading names in the same sector can score across valuation, profitability and dividend metrics, even when operating in the same space. This comparison does not declare a winner; investors should weigh these figures against their own research and risk appetite. Please read the disclaimer below before making any investment decision.

FAQs on Sun Pharma vs Cipla vs Dr Reddy's Laboratories

What is the market cap difference between Sun Pharma, Cipla and Dr Reddy's Laboratories?

Ans. As of September 2026, Sun Pharma has a market cap of approximately Rs 4,70,534 crore, Cipla is at approximately Rs 1,20,079 crore, and Dr Reddy's Laboratories is at approximately Rs 97,407 crore.

Which of the three has the highest PE ratio?

Ans. Among Sun Pharma, Cipla and Dr Reddy's Laboratories, the PE ratios stand at 38.90, 35.62 and 30.23 respectively as of September 2026.

Which of the three has the highest ROE?

Ans. Sun Pharma, Cipla and Dr Reddy's Laboratories post ROE of 13.73%, 11.26% and 11.07% respectively as of September 2026.

What is the 52-week range for Sun Pharma, Cipla and Dr Reddy's Laboratories?

Ans. Sun Pharma has traded between Rs 1,548.00 and Rs 2,046.90, Cipla between Rs 1,165.70 and Rs 1,673.00, and Dr Reddy's Laboratories between Rs 1,101.00 and Rs 1,414.90 over the past 52 weeks.

Which of these three stocks pays the highest dividend yield?

Ans. Sun Pharma, Cipla and Dr Reddy's Laboratories carry dividend yields of 0.82%, 0.88% and 0.69% respectively as of September 2026.

Which pharma stock has the highest market cap among Sun Pharma, Cipla and Dr Reddy's?

Ans. Sun Pharma has by far the largest market cap among the three at approximately Rs 4,70,534 crore, compared with Cipla at around Rs 1,20,079 crore and Dr Reddy's Laboratories at around Rs 97,407 crore.

Which of the three pharma stocks trades at the lowest valuation?

Ans. Dr Reddy's Laboratories trades at the lowest PE and PB multiples among the three, at 30.23 and 2.57 times book value respectively.

Is one of Sun Pharma, Cipla or Dr Reddy's Laboratories better than the others?

Ans. This comparison does not declare one stock better than another; each company scores differently across valuation, profitability and dividend metrics, and the right fit depends on an individual investor's own criteria and research.